story of the week
Talimogene Laherparepvec Plus Pembrolizumab for Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
J. Clin. Oncol 2022 Aug 23;[EPub Ahead of Print], JA Chesney, A Ribas, GV Long, JM Kirkwood, R Dummer, I Puzanov, C Hoeller, TF Gajewski, R Gutzmer, P Rutkowski, L Demidov, P Arenberger, SJ Shin, PF Ferrucci, A Haydon, J Hyngstrom, JV van Thienen, S Haferkamp, JM Guilera, BL Rapoport, A VanderWalde, SJ Diede, JR Anderson, S Treichel, EL Chan, S Bhatta, J Gansert, FS Hodi, H GogasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.